Drug intelligence / Profile preview

DS5361b

Development stage: Phase 1
Lead developer: Daiichi Sankyo
Modality: Small Molecules

Overview

**DS5361b** is an investigational small molecule developed by Daiichi Sankyo for advanced solid tumors. It is being evaluated in a Phase 1 first-in-human trial (NCT07182591) assessing safety, tolerability, pharmacokinetics, and preliminary efficacy as monotherapy and in combination with pembrolizumab, targeting patients with recurrent, metastatic, or unresectable tumors refractory to standard treatments, including those with high tumor mutational burden (TMB-H) or microsatellite instability-high (MSI-H) status. The trial includes dose escalation and expansion cohorts focusing on non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).[1][3][5][7][8]

Other names: DS5361bDS-5361bDS 5361b

Targets

NMD (Nonsense-mediated decay (NMD) machinery)

Beyond the preview

Go deeper on DS5361b.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS5361b.

Explore the full profile